Jinwon Life Sciences Publishes Research on Zika Virus mRNA Vaccine in International Journal

GeneOne Life Science announced on the 19th that the results of a study evaluating a Zika virus mRNA vaccine, jointly developed with research teams from the Korea Institute of Science and Technology (KIST) and The Catholic University of Korea, in animal models have been published in the internationally renowned journal Vaccine.

The title of the paper is "Immunogenicity and protection of a triple repeat domain III mRNA vaccine against Zika virus." The mRNA vaccine, named ‘3xEII,’ encodes the domain III of the Zika E protein repeated three times, effectively eliminating the Zika virus in mouse models, preventing Zika virus infection, and showing positive results in long-term immune responses.

A company representative explained, “This study was conducted as a project supported by the Ministry of Health and Welfare’s Vaccine Commercialization Business Group. The Zika virus is transmitted through mosquitoes and is known to cause serious congenital defects such as microcephaly when pregnant women are infected, but there is currently no approved vaccine.”

Park Young-geun, CEO of GeneOne Life Science, said, “The results of experiments on animal models with the Zika virus mRNA vaccine developed jointly with the research team confirmed effective immune responses such as the induction of neutralizing antibodies. This is a meaningful outcome and sufficient to be evaluated as a promising vaccine candidate against the Zika virus.”